Bessam Farjo
Research Subjects
Research Interests
Bessam Farjo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Nilofer Farjo
Farjo Hair Institute Manchester UK
3 shared publications - Ralf Paus
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33125, USA
3 shared publications - Jonathan Alan Hardman
Centre for Dermatology Research, Institute of Inflammation and Repair, University of Manchester, Manchester, UK
2 shared publications - Matthew Harries
Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M6 8HD, UK
2 shared publications - Talveen S. Purba
Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biosciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
2 shared publications - Andrew G. Messenger
Division of Clinical Medicine, University of Sheffield, UK
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (12) , e70186
Metabolic and Vascular Inflammation in Alopecia Areata: Linking Uric Acid, Lipid Imbalance and ICAM ‐1 Upregulation
Alopecia areata (AA) is an inflammatory hair loss disorder caused by an immune‐mediated attack of the hair follicle (HF) bulb. Active disease is characterised by a peribulbar proinflammatory infiltrate, HF immune privilege collapse and premature catagen induction, yet the underlying drivers of AA remain poorly understood. With comparable autoimmune inflammatory conditions displaying metabolic alterations, we hypothesised that AA is marked by similar pathobiological changes. To investigate this, we utilised an exploratory metabolomics‐based discovery liquid chromatography mass spectrometry (LC–MS) approach. This yielded 32 putatively annotated metabolites significantly altered between lesional and nonlesional AA scalp. Notably, 13‐HODE, a linoleic acid metabolite linked to vascular function, was decreased, whilst uric acid (UA), a purine degradation metabolite linked to vascular dysfunction, was increased in the lesional scalp. Moreover, serum LC–MS revealed elevated UA in AA compared to controls, which is linked to systemic endothelial dysfunction. CD31+/ICAM‐1+ immunofluorescence co‐expression analysis revealed elevated vascular inflammation and endothelial cell activation in the AA scalp. We also experimentally provoked the same response in ex vivo human HF culture via UA or fructose (which increases UA) supplementation. Interestingly, the fructose‐generating polyol pathway enzymes, AKR1B1 and SORD, are expressed in the HF, with significantly increased AKR1B1 immunoreactivity in lesional AA HFs, suggesting that fructose can be locally generated by the HF and may contribute to elevated UA levels in AA. Together, these metabolic changes point towards UA‐linked microvascular dysfunction in AA, inviting exploration of whether strategies to improve endothelial function and regulate UA are effective in managing AA.
- 12 December 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (12) , e70186
Open AccessMetabolic and Vascular Inflammation in Alopecia Areata: Linking Uric Acid, Lipid Imbalance and ICAM ‐1 Upregulation
Alopecia areata (AA) is an inflammatory hair loss disorder caused by an immune‐mediated attack of the hair follicle (HF) bulb. Active disease is characterised by a peribulbar proinflammatory infiltrate, HF immune privilege collapse and premature catagen induction, yet the underlying drivers of AA remain poorly understood. With comparable autoimmune inflammatory conditions displaying metabolic alterations, we hypothesised that AA is marked by similar pathobiological changes. To investigate this, we utilised an exploratory metabolomics‐based discovery liquid chromatography mass spectrometry (LC–MS) approach. This yielded 32 putatively annotated metabolites significantly altered between lesional and nonlesional AA scalp. Notably, 13‐HODE, a linoleic acid metabolite linked to vascular function, was decreased, whilst uric acid (UA), a purine degradation metabolite linked to vascular dysfunction, was increased in the lesional scalp. Moreover, serum LC–MS revealed elevated UA in AA compared to controls, which is linked to systemic endothelial dysfunction. CD31+/ICAM‐1+ immunofluorescence co‐expression analysis revealed elevated vascular inflammation and endothelial cell activation in the AA scalp. We also experimentally provoked the same response in ex vivo human HF culture via UA or fructose (which increases UA) supplementation. Interestingly, the fructose‐generating polyol pathway enzymes, AKR1B1 and SORD, are expressed in the HF, with significantly increased AKR1B1 immunoreactivity in lesional AA HFs, suggesting that fructose can be locally generated by the HF and may contribute to elevated UA levels in AA. Together, these metabolic changes point towards UA‐linked microvascular dysfunction in AA, inviting exploration of whether strategies to improve endothelial function and regulate UA are effective in managing AA.
- Open Access
- 26 May 2023
- Published by Wiley in Experimental Dermatology
- Vol. 32 (7) , 1174-1181
Male pattern hair loss: Can developmental origins explain the pattern?
Male pattern hair loss (MPHL), also referred to as male androgenetic alopecia (AGA) is the most common type of non‐scarring progressive hair loss, with 80% of men suffering from this condition in their lifetime. In MPHL, the hair line recedes to a specific part of the scalp which cannot be accurately predicted. Hair is lost from the front, vertex, and the crown, yet temporal and occipital follicles remain. The visual effect of hair loss is due to hair follicle miniaturisation, where terminal hair follicles become dimensionally smaller. Miniaturisation is also characterised by a shortening of the growth phase of the hair cycle (anagen), and a prolongation of the dormant phase (kenogen). Together, these changes result in the production of thinner and shorter hair fibres, referred to as miniaturised or vellus hairs. It remains unclear why miniaturisation occurs in this specific pattern, with frontal follicles being susceptible while occipital follicles remain in a terminal state. One main factor we believe to be at play, which will be discussed in this viewpoint, is the developmental origin of the skin and hair follicle dermis on different regions of the scalp.
- 26 May 2023
- Published by Wiley in Experimental Dermatology
- Vol. 32 (7) , 1174-1181
Open AccessMale pattern hair loss: Can developmental origins explain the pattern?
Male pattern hair loss (MPHL), also referred to as male androgenetic alopecia (AGA) is the most common type of non‐scarring progressive hair loss, with 80% of men suffering from this condition in their lifetime. In MPHL, the hair line recedes to a specific part of the scalp which cannot be accurately predicted. Hair is lost from the front, vertex, and the crown, yet temporal and occipital follicles remain. The visual effect of hair loss is due to hair follicle miniaturisation, where terminal hair follicles become dimensionally smaller. Miniaturisation is also characterised by a shortening of the growth phase of the hair cycle (anagen), and a prolongation of the dormant phase (kenogen). Together, these changes result in the production of thinner and shorter hair fibres, referred to as miniaturised or vellus hairs. It remains unclear why miniaturisation occurs in this specific pattern, with frontal follicles being susceptible while occipital follicles remain in a terminal state. One main factor we believe to be at play, which will be discussed in this viewpoint, is the developmental origin of the skin and hair follicle dermis on different regions of the scalp.
- 1 July 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (7) , 1633-1645.e13
Dermal Adipose Tissue Secretes HGF to Promote Human Hair Growth and Pigmentation
- 1 July 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (7) , 1633-1645.e13
Dermal Adipose Tissue Secretes HGF to Promote Human Hair Growth and Pigmentation
- 1 February 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (2) , 334-344
Inhibition of Shh Signaling through MAPK Activation Controls Chemotherapy-Induced Alopecia
- 1 February 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (2) , 334-344
Inhibition of Shh Signaling through MAPK Activation Controls Chemotherapy-Induced Alopecia
- Open Access
- 29 May 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (5) , 964-966
Does mitochondrial dysfunction of hair follicle epithelial stem cells play a role in the pathobiology of lichen planopilaris?
Lichen planopilaris (LPP) is a difficult to treat condition leading to permanent hair loss and scarring. Pathobiologically, LPP shows T‐ cell mediated interferon‐γ driven loss of keratin 15 (K15) positive hair follicle (HF) epithelial stem cells (eHFSCs) due to immune privilege (IP) collapse and pathological epithelial‐mesenchymal transition (EMT). This exhausts the eHFSC pool; impacting the HF’s capacity to regenerate and cycle and ultimately resulting in HF destruction, fibrosis and scarring.
- 29 May 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (5) , 964-966
Open AccessDoes mitochondrial dysfunction of hair follicle epithelial stem cells play a role in the pathobiology of lichen planopilaris?
Lichen planopilaris (LPP) is a difficult to treat condition leading to permanent hair loss and scarring. Pathobiologically, LPP shows T‐ cell mediated interferon‐γ driven loss of keratin 15 (K15) positive hair follicle (HF) epithelial stem cells (eHFSCs) due to immune privilege (IP) collapse and pathological epithelial‐mesenchymal transition (EMT). This exhausts the eHFSC pool; impacting the HF’s capacity to regenerate and cycle and ultimately resulting in HF destruction, fibrosis and scarring.